Stefanie Bärthel

Stefanie Bärthel

Auto-generated profile, based on publicly available information

Stefanie Bärthel

Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CFChiara Falcomatà
Chiara Falcomatà
SBStefanie Bärthel
Stefanie Bärthel
GSGünter Schneider
Günter Schneider
RRRoland Rad
Roland Rad
MSMarc Schmidt-Supprian
Marc Schmidt-Supprian
DSDieter Saur
Dieter Saur
Immunotherapies have shown benefits across a range of human cancers, but not pancreatic ductal adenocarcinoma (PDAC). Recent evidence suggests that the immunosuppressive tumor microenvironment (TME) constitutes an important roadblock to their efficacy. The landscape of the TME differs substantially across PDAC subtypes, indicating context-specific principles of immunosuppression. In this review, we discuss how PDAC cells, the local TME, and systemic host and environmental factors drive immunosuppression in context. We argue that unraveling the mechanistic drivers of the context-specific modes of immunosuppression will open new possibilities to target PDAC more efficiently by using multimodal (immuno)therapeutic interventions. Significance: Immunosuppression is an almost universal hallmark of pancreatic cancer, although this tumor entity is highly heterogeneous across its different subtypes and phenotypes. Here, we provide evidence that the diverse TME of pancreatic cancer is a central executor of various different context-dependent modes of immunosuppression, and discuss key challenges and novel opportunities to uncover, functionalize, and target the central drivers and functional nodes of immunosuppression for therapeutic exploitation.

23 March 2023 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
SBStefanie Bärthel
Stefanie Bärthel
CFChiara Falcomatà
Chiara Falcomatà
RRRoland Rad
Roland Rad
FTFabian J. Theis
Fabian J. Theis
DSDieter Saur
Dieter Saur

31 January 2022 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
CFChiara Falcomatà
Chiara Falcomatà
SBStefanie Bärthel
Stefanie Bärthel
SWSebastian A Widholz
Sebastian A Widholz
CSChristian Schneeweis
Christian Schneeweis
JMJuan José Montero
Juan José Montero
DSDieter Saur
Dieter Saur

16 June 2022 in Nature Methods
Verified
Journal Article
Closed access
PDF file
PGPiero Giansanti
Piero Giansanti
PSPatroklos Samaras
Patroklos Samaras
YBYangyang Bian
Yangyang Bian
CMChen Meng
Chen Meng
ACAndrea Coluccio
Andrea Coluccio
BKBernhard Kuster
Bernhard Kuster

10 December 2024 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
APAristeidis Papargyriou
Aristeidis Papargyriou
MNMulham Najajreh
Mulham Najajreh
DCDavid P. Cook
David P. Cook
CMCarlo H. Maurer
Carlo H. Maurer
SBStefanie Bärthel
Stefanie Bärthel
MRMaximilian Reichert
Maximilian Reichert
In patients with pancreatic ductal adenocarcinoma (PDAC), intratumoural and intertumoural heterogeneity increases chemoresistance and mortality rates. However, such morphological and phenotypic diversities are not typically captured by organoid models of PDAC. Here we show that branched organoids embedded in collagen gels can recapitulate the phenotypic landscape seen in murine and human PDAC, that the pronounced molecular and morphological intratumoural and intertumoural heterogeneity of organoids is governed by defined transcriptional programmes (notably, epithelial-to-mesenchymal plasticity), and that different organoid phenotypes represent distinct tumour-cell states with unique biological features in vivo. We also show that phenotype-specific therapeutic vulnerabilities and modes of treatment-induced phenotype reprogramming can be captured in phenotypic heterogeneity maps. Our methodology and analyses of tumour-cell heterogeneity in PDAC may guide the development of phenotype-targeted treatment strategies.

8 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JSJonathan J. Swietlik
Jonathan J. Swietlik
SBStefanie Bärthel
Stefanie Bärthel
CFChiara Falcomatà
Chiara Falcomatà
DFDiana Fink
Diana Fink
ASAnkit Sinha
Ankit Sinha
FMFelix Meissner
Felix Meissner
Cell-selective proteomics is a powerful emerging concept to study heterocellular processes in tissues. However, its high potential to identify non-cell-autonomous disease mechanisms and biomarkers has been hindered by low proteome coverage. Here, we address this limitation and devise a comprehensive azidonorleucine labeling, click chemistry enrichment, and mass spectrometry-based proteomics and secretomics strategy to dissect aberrant signals in pancreatic ductal adenocarcinoma (PDAC). Our in-depth co-culture and in vivo analyses cover more than 10,000 cancer cell-derived proteins and reveal systematic differences between molecular PDAC subtypes. Secreted proteins, such as chemokines and EMT-promoting matrisome proteins, associated with distinct macrophage polarization and tumor stromal composition, differentiate classical and mesenchymal PDAC. Intriguingly, more than 1,600 cancer cell-derived proteins including cytokines and pre-metastatic niche formation-associated factors in mouse serum reflect tumor activity in circulation. Our findings highlight how cell-selective proteomics can accelerate the discovery of diagnostic markers and therapeutic targets in cancer.